Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely - 2Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- 3Germany expresses 'great concern' over Israel's new death penalty law
- 4Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- 5Pentagon advances Golden Dome missile defense with new Space Force contracts
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
- Jamie Dimon warns Iran war could drive inflation, interest rates higher
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- Astonishing interstellar comet captured in new images by NASA Mars missions
- Figure out How to Get the Best Open Record Rewards
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- Volkswagen Just Built a Plug-In Tiguan for China That America Doesn’t Get
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
